Decoding Biopharma Industry Partnership Signals

What current biopharma activity reveals about R&D priorities, external innovation, and what it means for academic-industry partnerships Biopharma companies are continually making decisions about where to allocate R&D capital, which scientific and therapeutic areas to pursue, which capabilities to source externally, and what data and evidence are needed to advance programs. Partnerships, licensing agreements, acquisitions, strategic research collaborations, and investment activity provide a view into those priorities and how companies are approaching external innovation. In this Fall 2026 edition of Decoding Biopharma Industry Partnership Signals, Ari Marcellino, Assistant Director of Industry Research Partnerships, will break down several patterns emerging across current industry activity, including: How biopharma companies are evaluating and accessing external innovationWhere research capabilities and enabling technologies are creating value in industry R&DHow evidence, validation, an...